Timothy A. Springer - Dec 19, 2024 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Timothy A. Springer
Stock symbol
RNAC
Transactions as of
Dec 19, 2024
Transactions value $
$965,021
Form type
4
Date filed
12/23/2024, 05:20 PM
Previous filing
Nov 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Purchase $197K +11.3K +0.13% $17.39 8.47M Dec 19, 2024 Direct F1
transaction RNAC Common Stock Purchase $193K +10.5K +0.12% $18.35 8.48M Dec 19, 2024 Direct F2
transaction RNAC Common Stock Purchase $63.9K +3.38K +0.04% $18.93 8.48M Dec 19, 2024 Direct F3
transaction RNAC Common Stock Purchase $413K +21.8K +0.26% $18.94 8.5M Dec 20, 2024 Direct F4
transaction RNAC Common Stock Purchase $98.4K +5.18K +0.06% $19.00 8.51M Dec 23, 2024 Direct F5
holding RNAC Common Stock 331K Dec 19, 2024 By wife
holding RNAC Common Stock 530K Dec 19, 2024 See Footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.81 to $17.7912. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.82 to $18.8125. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.82 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.73 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.98 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F6 Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.